Cassava Sciences: Insider Buying by the CEO Totals $534,743
Reading Time: 2 minutes
In recent months, Cassava Sciences (SAVA) has undertaken a strategic realignment that strongly focuses on pipeline management and the development of the lead drug candidate Simufilam. Recent press releases emphasize a shift in clinical priorities. After failing to meet primary endpoints in a Phase 3 study for Alzheimer's disease, the company is now placing greater emphasis on exploring Simufilam for other diseases. Specifically, there are promising preclinical data suggesting efficacy against seizure disorders associated with Tuberous Sclerosis...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
